|
시장보고서
상품코드
2076000
소아용 항간질제 시장 : 약제 유형별, 투여 경로별, 유통 채널별, 지역별Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
소아용 항간질제 시장은 2026년에 15억 9,940만 달러 규모가 된다고 추정되고 있어 2033년까지 27억 7,680만 달러에 이를 것으로 예상되고 있습니다. 2026년부터 2033년까지 CAGR 8.2%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 15억 9,940만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간 CAGR : | 8.20% | 2033년 시장 규모 예측 : | 27억 7,680만 달러 |
간질은 전 세계 모든 연령대의 사람들에게 영향을 미치는 흔한 신경 질환입니다. 그러나 간질 환자의 약 70%가 성인이 되기 전에 진단을 받기 때문에 소아에서 더 많이 나타납니다. 항간질제는 발작 관리와 간질을 앓고 있는 소아 환자의 삶의 질(QOL) 향상에 있어 매우 중요한 역할을 하고 있습니다. 이러한 약물은 뇌 내의 비정상적인 신경세포의 방전이나 동조를 조절함으로써 발작을 예방합니다. 최근 몇 년간 광범위한 조사가 진행되어, 기존의 소아용 약제보다 효과가 뛰어나고 부작용이 적은 차세대 항간질제가 개발 및 승인되었습니다. 이를 통해 간질을 앓고 있는 소아의 복약 순응도와 치료 성과에 긍정적인 영향을 미치고 있습니다. 소아 뇌전증은 외상, 분만 시의 합병증, 또는 유전성 질환에 의해 유발될 수 있습니다. 수막염 등의 뇌 감염증으로 인한 간질은 “증상성 간질”라고 불리며, 유전 관련 질환은 “특발성 간질”라고 불립니다.
시장 역학
세계 소아용 항간질제 시장은 소아 간질 유병률 증가에 힘입어 성장하고 있습니다. 세계보건기구(WHO)에 따르면, 전 세계적으로 약 1%의 어린이가 간질을 앓고 있습니다. 이에 더해, 의료비 지출 증가, 간질 치료에 대한 인식 제고, 그리고 새로운 항간질제의 도입과 같은 요인들이 시장 성장을 뒷받침하고 있습니다. 그러나 이 시장에는 의약품 개발에 수반되는 높은 비용이나 소아용 의약품 승인과 관련된 엄격한 규제 등 일정한 제약이 존재합니다. 또한, 발달 단계에 있는 소아의 신경계에 미치는 항간질제의 부작용도 과제로 대두되고 있습니다. 한편, 질환 수정 요법에 대한 지속적인 연구와 맞춤형 항간질제 치료법의 개발은 향후 시장 관계자들에게 주목할 만한 기회를 제공할 것입니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 성장 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 소아용 항간질제 시장의 주요 기업 프로파일을 소개했습니다.
- 본 조사에서 다룬 주요 기업으로는 사노피, 에자이 주식회사, 화이자, UCB S.A., 사노비온 파마슈티컬스, 애보트, 재즈 파마슈티컬스, 오비드 테라퓨틱스, SK 바이오파마슈티컬스, 알렉사 파마슈티컬스, 다이쇼 제약 홀딩스 주식회사, 마리나스 파마슈티컬스, 제논 파마슈티컬스, H. 룬드베크, 그리고 테바 파마슈티컬 인더스트리즈 등이 포함됩니다.
- 본 보고서에서 얻을 수 있는 인사이트는 각 기업의 마케팅 담당자 및 경영진이 향후 제품 출시, 제품 라인업 개편, 시장 확대 및 마케팅 전략과 관련하여 충분한 정보를 바탕으로 의사결정을 내리는 데 도움이 됩니다.
- 이 세계 소아용 항간질제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 소아용 항간질제 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 소아용 항간질제 시장 : 약제 유형별, 2021-2033년
제5장 세계의 소아용 항간질제 시장 : 투여 경로별, 2021-2033년
제6장 세계의 소아용 항간질제 시장 : 유통 채널별, 2021-2033년
제7장 세계의 소아용 항간질제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
JHS 26.07.09Anti-Epileptic Drugs for Pediatrics Market is estimated to be valued at USD 1,599.4 Mn in 2026 and is expected to reach USD 2,776.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,599.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.20% | 2033 Value Projection: | USD 2,776.8 Mn |
Epilepsy is a common neurological disorder that affects people of all ages globally. However, it is more prevalent in children as almost 70% of epilepsy cases are diagnosed before reaching adulthood. Anti-epileptic drugs play a crucial role in managing seizures and improving quality of life for pediatric patients suffering from epilepsy. These medications work by controlling abnormal neuronal firing and synchrony in the brain to prevent seizures. In recent years, extensive research has led to the development and approval of newer generation anti-epileptic drugs that are more effective and have less side effects than the earlier drugs for pediatric use. This has positively impacted medication adherence and treatment outcomes for children with epilepsy. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while a genetics related condition is called idiopathic epilepsy.
Market Dynamics
The global anti-epileptic drugs for pediatrics market is driven by the growing prevalence of epilepsy among children. According to the World Health Organization (WHO), epilepsy affects around 1% of children worldwide. Besides this, factors such as increasing healthcare expenditures, rising awareness about epilepsy treatment, and introduction of newer anti-epileptic drugs are fueling the market growth. However, the market faces certain restraints such as high costs associated with drug development and stringent regulations for the approval of pediatric drugs. Moreover, adverse effects of anti-epileptic drugs on developing neurological system of children poses challenges. On the positive side, ongoing research on disease modifying therapies and development of personalized anti-epileptic drug regimens present notable opportunities for market players in the future.
Key features of the study:
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global anti-epileptic drugs for pediatrics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered as part of this study include Sanofi, Eisai Co., Ltd., Pfizer Inc., UCB S.A., Sunovion Pharmaceuticals Inc., Abbott, Jazz Pharmaceuticals plc, Ovid Therapeutics Inc., SK BIOPHARMACEUTICALS, Alexza Pharmaceuticals, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Marinus Pharmaceuticals, Inc., Xenon Pharmaceuticals Inc., H. Lundbeck A/S, and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics
- The global anti-epileptic drugs for pediatrics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-epileptic drugs for pediatrics market
Detailed Segmentation:
- Global Anti-Epileptic Drugs for Pediatrics Market, Drug Type (Revenue, USD Mn, 2021 - 2033)
- First generation anti-epileptic drugs
- Second generation anti-epileptic drugs
- Third generation anti-epileptic drugs
- Global Anti-Epileptic Drugs for Pediatrics Market, Route of Administration:
- Oral
- Injectable
- Others (Nasal, etc.)
- Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Sanofi
- Eisai Co., Ltd.
- Pfizer Inc.
- UCB S.A.
- Sunovion Pharmaceuticals Inc.
- Abbott
- Jazz Pharmaceuticals plc
- Ovid Therapeutics Inc.
- SK BIOPHARMACEUTICALS
- Alexza Pharmaceuticals, Inc.
- Taisho Pharmaceutical Holdings Co., Ltd.
- Xenon Pharmaceuticals Inc.
- Lundbeck A/S
- Teva Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trend Analysis
- Market Dynamics
- Drivers
- Increasing incidence of neurological disorders
- Increasing research and development activities
- Restraints
- Increasing product recalls by regulatory authorities
- Side effects of anti-epileptic drugs
- Market Opportunities
- Untapped emerging markets
- The rising demand for targeted therapy
- Drivers
- Impact Analysis
- Regulatory Guidelines
- Product Launches
- Key Development
- PEST Analysis
- PORTER's Analysis
- Regulatory Scenario
- Mergers and Acquisitions
- Manufacturer Revenue
- Healthcare Spending by Country
4. Global Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, 2021 - 2033, (US$ Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- First generation anti-epileptic drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Second generation anti-epileptic drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Third generation anti-epileptic drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
5. Global Anti-Epileptic Drugs for Pediatrics Market, By Route of Administration, 2021 - 2033, (US$ Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Injectable
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Others (Nasal, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
6. Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
7. Global Anti-Epileptic Drugs for Pediatrics Market, By Region, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021-2033, (US$ Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlight
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- UCB S.A.
- Company Highlight
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sunovion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Jazz Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ovid Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- SK BIOPHARMACEUTICALS
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alexza Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Taisho Pharmaceutical Holdings Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Marinus Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Xenon Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
